A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT03861481 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions

DRUG: Rozanolixizumab
OTHER: Placebo

Sponsor

UCB Biopharma S.P.R.L.